Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Mini-review: antibody therapeutics targeting G protein-coupled receptors and ion channels

Mini-review: antibody therapeutics targeting G protein-coupled receptors and ion channels Antibodies are now well established as therapeutics with many additional advantages over small molecules and peptides relative to their selectivity, bioavailability, half-life and effector function. Major classes of membrane-associated protein targets include G protein-coupled receptors (GPCRs) and ion channels that are linked to a wide range of disease indications across all therapeutic areas. This mini-review summarizes the antibody target landscape for both GPCRs and ion channels as well as current progress in the respective research and development pipelines with some example case studies highlighted from clinical studies, including those being evaluated for the treatment of symptoms in COVID-19 infection. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Antibody Therapeutics Oxford University Press

Mini-review: antibody therapeutics targeting G protein-coupled receptors and ion channels

Hutchings, Catherine J
Antibody Therapeutics , Volume 3 (4): 8 – Dec 9, 2020
Download PDF
8 pages

Loading next page...
 
/lp/oxford-university-press/mini-review-antibody-therapeutics-targeting-g-protein-coupled-ERZ086txhl
Publisher
Oxford University Press
Copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of Antibody Therapeutics.
eISSN
2516-4236
DOI
10.1093/abt/tbaa023
Publisher site
See Article on Publisher Site

Abstract

Antibodies are now well established as therapeutics with many additional advantages over small molecules and peptides relative to their selectivity, bioavailability, half-life and effector function. Major classes of membrane-associated protein targets include G protein-coupled receptors (GPCRs) and ion channels that are linked to a wide range of disease indications across all therapeutic areas. This mini-review summarizes the antibody target landscape for both GPCRs and ion channels as well as current progress in the respective research and development pipelines with some example case studies highlighted from clinical studies, including those being evaluated for the treatment of symptoms in COVID-19 infection.

Journal

Antibody Therapeutics – Oxford University Press

Published: Dec 9, 2020

Keywords: GPCR; ion channel; complex membrane proteins; monoclonal antibody; nanobody; antibody targets; target landscape; erenumab; mogamulizumab; leronlimab; avdoralimab

References

  • Trends in GPCR drug discovery: new agents, targets and indications
    Hauser, AS; Attwood, MM; Rask-Andersen, M
  • Shaw Stockbroking Company Report
    Vincent, D
  • An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases
    Heng, BC; Aubel, D; Fussenegger, M
  • Ion channels as therapeutic antibody targets
    Hutchings, CJ; Colussi, P; Clarke, TG
  • Development of therapeutic antibodies to G protein-coupled receptors and ion channels: opportunities, challenges and their therapeutic potential in respiratory diseases
    Douthwaite, JA; Finch, DK; Mustelin, T
  • Opportunities for therapeutic antibodies directed at G-protein-coupled receptors
    Hutchings, CJ; Koglin, M; Olson, WC
  • Generating therapeutic monoclonal antibodies to complex multi-spanning membrane targets: overcoming the antigen challenge and enabling discovery strategies
    Dodd, R; Schofield, DJ; Wilkinson, T
  • A review of antibody-based therapeutics targeting G protein-coupled receptors: an update
    Hutchings, CJ
  • Discovery of functional antibodies targeting ion channels
    Wilkinson, TC; Gardener, MJ; Williams, WA
  • Screening strategies for the discovery of ion channel monoclonal antibodies
    Colley, CS; England, E; Linley, JE
  • Antibodies to watch in 2019
    Kaplon, H; Reichert, JM
  • Ion channels as therapeutic targets for viral infections: further discoveries and future perspectives
    Charlton, FW; Pearson, HM; Hover, S
  • Emerging roles of viroporins encoded by DNA viruses: novel targets for antivirals?
    Royle, J; Dobson, SJ; Müller, M
  • A sialylated voltage-dependent Ca2+ channel binds hemagglutinin and mediates influenza a virus entry into mammalian cells
    Fujioka, Y; Nishide, S; Ose, T
  • A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications
    Changeux, JP; Amoura, Z; Rey, FA
  • Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
    , Ou; Liu, Y; Lei, X
  • Antibodies to watch in 2020
    Kaplon, H; Muralidharan, M; Schneider, Z
  • Disruption of the CCL5/RANTES-CCR5 pathway restores immune homeostasis and reduces plasma viral load in critical COVID-19
    Patterson, BK; Seethamraju, H; Dhody, K
  • Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5
    Olson, WC; Rabut, GE; Nagashima, KA
  • CytoDyn Requests “Fast Track Approval” for COVID-19 Patients from U.K.’s Regulatory Agency MHRA Based on its Top-line Report Showing Statistically Significant Endpoint, NEWS2 (p<0.023) and Notable Safety Results
  • Complement as a target in COVID-19? Nat
    Risitano, AM; Mastellos, DC; Huber-Lang, M
  • Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis
    Carvelli, J; Demaria, O; Vély, F
  • VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis
    Low, S; , Wu; Jerath, K
  • Engineering antibody reactivity for efficient derivitization to generate Na(V)1.7 inhibitory GpTx-1 peptide-antibody conjugates
    Biswas, K; Nixey, TE; Murray, JK
  • Engineering Na(V)1.7 inhibitory JzTx-V with a potency and basicity profile suitable for antibody conjugation to enhance pharmacokinetics
    Murray, JK; Wu, B; Tegley, CM
  • Anti-ORAI1 antibody DS-2741a, a specific CRAC channel blocker, shows ideal therapeutic profiles for allergic disease via suppression of aberrant T-cell and mast cell activation
    Aki, A; Tanaka, K; Nagaoka, N
  • CRAC channels and Ca2+ signaling in mast cells
    Di Capite, J; Parekh, AB
  • Function-based high-throughput screening for antibody antagonists and agonists against G protein-coupled receptors
    Ren, H; Li, J; Zhang, N
  • Therapeutic antibodies directed at G protein-coupled receptors
    Hutchings, CJ; Koglin, M; Marshall, FH
  • Structure-guided drug discovery of a single-domain antibody agonist against human apelin receptor
    Ma, Y; Ding, Y; Song, X
  • Structures of human Na(v)1.7 channel in complex with auxiliary subunits and animal toxins
    Shen, H; Liu, D; Wu, K